Escient Pharmaceuticals

pause hold stop delay
Biotech

Incyte's $750M buyout rocked by pause on key trial, asset cull

Less than six months after closing the deal, Incyte has paused a key study over preclinical toxicology findings and axed another program altogether.
Nick Paul Taylor Nov 19, 2024 4:12am
Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand

Incyte, fresh off gaining MorphoSys drug, buys Escient for $750M

Apr 23, 2024 10:43am
cash

Sanofi-backed Escient bags $120M series C

Nov 28, 2022 11:06am
Patients undergoing kidney dialysis must have their hydration level closely monitored a newly-developed portable sensor make

Sanofi backs Escient as it kick-starts first clinical test

Sep 15, 2020 8:15am